Clinical

We should look forward to a safe, effective vaccine for coronavirus disease 2019 (COVID-19) but not expect it to be the ultimate panacea.

Ibrutinib can lead to side effects, causing some physicians to consider reducing the dose or temporarily halting therapy, but that risks disease flares, a new study finds.

The drug, mastinib, reduced the chance of a confirmed disability progression by 37% in phase 2b/3 study results.

With more multiple sclerosis (MS) treatments becoming available, it is now possible to better personalize approaches, explained speakers during a session at MSVirtual 2020: 8th Joint ACTRIMS-ECTRIMS Meeting.

Post hoc data from 2 late-stage studies about siponimod, sold as Mayzent by Novartis, illustrated improved cognitive processing speed and delayed time to disability in multiple sclerosis.

The broadest real-life study of dupilumab in atopic dermatitis (AD) found significant improvements in adults with moderate to severe AD that were even greater than the results reported in clinical trials.

A minority of patients with multiple sclerosis (MS) have primary progressive disease, and it has few treatment options.

In recent years, the number of children diagnosed with additional autoimmune diseases accompanying type 1 diabetes (T1D) has increased, according to a study published in Frontiers in Endocrinology.

While coronavirus disease 2019 (COVID-19) is largely a respiratory disease, it is actually a systemic disease that has a wide range of effects and postinfection sequelae that aren’t yet fully known, said Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.

There are now multiple therapeutic options available for spinal muscular atrophy (SMA), a disease once considered incurable; however, there remains a need for additional treatments and better ways to predict treatment response.

In clinical practice, lasmiditan may be given together with propranolol; investigators wanted to test the cardiovascular effects of coadministration.

A significant number of patients who undergo chimeric antigen receptor (CAR) T-cell therapy will experience severe neurotoxicity. A new study could help doctors better predict which patients are at risk.